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Objectives. We compared dipyridamole technetium-99m (Tc-
99m) tetrofosmin and thallium-201 (Tl-201) single-photon emis-
sion computed tomographic (SPECT) imaging with respect to the
detection rate of perfusion abnormalities in 26 patients with
angiographic coronary artery disease (CAD).
Background. Experimental studies have shown that myocardial
extraction of Tc-99m tetrofosmin is lower than that of Tl-201 at
high flow rates, resulting in less severe defects with vasodilator
stress. It is uncertain whether this results in a lower sensitivity
than Tl-201 for detecting coronary stenoses with vasodilator stress
in patients.
Methods. Twenty-six patients with CAD underwent both dipyr-
idamole Tl-201 and Tc-99m tetrofosmin SPECT. Tomographic
images were scored for initial defects and the presence of revers-
ibility. Defect magnitude was computer quantitated.
Results. Of the 26 patients, 25 had defects on both Tl-201 and
Tc-99m tetrofosmin SPECT images. Of 340 segments analyzed,
102 had defects by Tl-201 and 92 by Tc-99m tetrofosmin (p 5 NS).
Whereas Tl-201 detected 27 fixed defects in 12 patients, Tc-99m
tetrofosmin identified 37 fixed defects in 14 patients (p 5 NS). In
contrast, Tl-201 identified more reversible and partially reversible
defects than did Tc-99m tetrofosmin (89 vs. 55, p 5 0.002). The
average defect magnitude (percent normal) was similar for defects
concordantly graded as fixed (38 6 3.0% for Tl-201 vs. 42 6 4%
[mean 6 SEM] for Tc-99m tetrofosmin, p 5 NS). The average
defect magnitude for defects concordantly graded as completely
reversible was significantly more severe on Tl-201 than on Tc-99m
tetrofosmin (49 6 3% vs. 58 6 3%) SPECT images. A significantly
greater defect magnitude for Tl-201 was also found for defects
concordantly classified as partly reversible (30 6 4% for Tl-201 vs.
45 6 5% for Tc-99m tetrofosmin).
Conclusions. With dipyridamole stress, 1) at least one defect
was seen on both Tl-201 and Tc-99m tetrofosmin SPECT images;
2) Tc-99m tetrofosmin SPECT identified fewer reversible defects
than did Tl-201, but showed a similar number of fixed defects; 3)
the magnitude of reversible defects seen on Tc-99m tetrofosmin
images was less, whereas fixed defects were similar for both
tracers; 4) reversible defects seen on Tl-201 and not on Tc-99m
tetrofosmin SPECT images were predominantly regions perfused
by mild coronary stenoses.
(J Am Coll Cardiol 1998;31:331–7)
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Technetium-99m (Tc-99m) tetrofosmin is a lipophilic, cationic
perfusion agent that, like Tc-99m sestamibi, is an alternative to
thallium-201 (Tl-201) for stress imaging. Experimental animal
studies have demonstrated that the myocardial extraction of
Tc-99m tetrofosmin plateaus at flow rates .1.7 3 normal
(1,2). This plateau is reached earlier with Tc-99m tetrofosmin
than with Tl-201 and Tc-99m sestamibi when the tracer is
administered during adenosine-induced vasodilation. The goal
of this study was to compare regional myocardial uptake of
Tc-99m tetrofosmin versus Tl-201 during dipyridamole stress
testing in patients with angiographically proven coronary ar-
tery disease (CAD). Both qualitative and quantitative analyses
of the resultant scans were undertaken.
Methods
Study patients. The study included 26 consecutive male
patients (mean [6SD] age 62 6 9 years, range 44 to 75)
referred to the cardiology section of the Veterans Affairs
Medical Center in Salem, Virginia, for evaluation of symptoms
suggestive of CAD. Patients were included in the study if they
had undergone cardiac catheterization demonstrating signifi-
cant stenosis (.50%) of at least one major coronary artery or
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if they had had a dipyridamole Tl-201 single-photon emission
computed tomographic (SPECT) scan showing myocardial
perfusion abnormalities suggestive of CAD. They were ex-
cluded from the study if they had been admitted to the hospital
with unstable angina for ,48 h; demonstrated a left bundle
branch block pattern on a 12-lead electrocardiogram (ECG);
had hemodynamic instability, severe congestive heart failure or
severe valvular heart disease, or a combination of these; were
actively taking drugs containing theophylline; or had recent
history of bronchospasm. All patients signed a written in-
formed consent before entering the study. The research pro-
tocol was approved by the Human Studies Committee of the
Veterans Affairs Medical Center.
Study protocol. All patients underwent cardiac catheteriza-
tion and coronary angiography, either as the initial diagnostic
test to confirm CAD or after the acquisition of a dipyridamole
Tl-201 SPECT scan showing myocardial perfusion abnormali-
ties. All patients underwent two dipyridamole stress tests and
coronary angiography within 14 days. Twenty-one patients
underwent dipyridamole Tl-201 SPECT imaging as the initial
test, and five patients underwent Tc-99m tetrofosmin SPECT
as the initial test. If the dipyridamole tests were performed on
consecutive days, as was the case for patients who had under-
gone coronary angiography first, Tl-201 tests were performed
first, followed by the Tc-99m tetrofosmin study.
Dipyridamole stress protocol. Similar protocols were fol-
lowed for both Tc-99m tetrofosmin and Tl-201 dipyridamole
studies. Patients fasted for at least 8 h before the study. Drugs
and foods containing methylxanthines were excluded. All
nitroglycerin preparations were discontinued for at least 24 h
before the test. An intravenous catheter was inserted in an
antecubital vein. Dipyridamole was administered intravenously
at a rate of 0.56 mg/kg body weight (maximum of 60 mg,
diluted in 40 ml of normal saline) over 4 min, while the patient
rested in the supine position. The radiopharmaceutical agent
(Tl-201 or Tc-99m tetrofosmin) was given by bolus injection
3 min after the completion of dipyridamole infusion. Vital
signs and the 12-lead ECG were monitored and recorded
before, during and for 8 min after dipyridamole administra-
tion. Intravenous aminophylline was administered in the event
of severe side effects or symptoms induced by dipyridamole.
Tl-201 imaging protocol. A bolus of Tl-201 (3.0 to 3.5 mCi)
was injected intravenously 3 min after the completion of
intravenous infusion of dipyridamole. SPECT myocardial im-
aging was begun within 15 min, using standard views. Delayed
images were obtained 3 to 4 h later.
Tc-99m tetrofosmin imaging. Tc-99m tetrofosmin was pre-
pared from freeze-dried vials (Medi-Physics, Inc., Amersham
Healthcare), with each vial containing a sterile, nonpyrogenic,
lyophilized mixture of 0.23 mg of Tc-99m tetrofosmin, 0.03 mg
of stannous chloride dihydrate, 0.32 mg of disodium sulfosa-
licylate, 1.0 mg of sodium D-gluconate and 1.8 mg of sodium
hydrogen carbonate. The lyophilized powder was sealed under
nitrogen atmosphere with rubber septum. Each vial was recon-
stituted according to the method described by Zaret et al. (3).
In contrast to the stress–rest protocol used for Tl-201 imaging,
a 1-day rest–stress injection protocol was used for Tc-99m
tetrofosmin SPECT imaging. A dose of 7 to 8 mCi of Tc-99m
tetrofosmin was injected intravenously at rest. Myocardial
SPECT scanning was performed after a waiting period of 30 to
60 min. A minimum of 1 h was allowed after the completion of
the rest imaging and before intravenous dipyridamole was
infused. A bolus injection of 30 to 35 mCi of Tc-99m tetrofos-
min followed the infusion of dipyridamole by 3 min, and
myocardial SPECT images were acquired 30 to 60 min later.
SPECT acquisition and quantitative analysis. Both Tc-
99m tetrofosmin and Tl-201 SPECT studies were acquired on
a Sopha gamma camera (model DSX) with 180° contoured
acquisition centered on the heart. The same filters were used
for both tracers. Tl-201 SPECT acquisition was performed
using 32 steps of 40 s each in a 25% window centered on the
80-keV gamma-ray peak of Tl-201. Tc-99m tetrofosmin
SPECT studies were acquired using 32 steps of 25 s each in a
20% window centered on the 140-keV gamma-ray peak of
Tc-99m tetrofosmin. Myocardial images were aligned in simi-
lar fashion in all patients, and the same orientation was used.
Quantitative analysis entails use of a conventional polar map
representing maximal pixel values obtained from searching
radii crossing the myocardial wall. The polar maps were
divided into 14 segments, and the average of all values within
each segment was used as the quantitative variable. The 14
segments included six proximal short-axis, six distal short-axis
and two apical segments (Fig. 1). Segments on the polar maps
were divided to represent approximately equal myocardial
volume samples accounting for the mapping distortion of the
polar map. The segment with the highest average was set to
100%, and all other segments were normalized to that seg-
ment. The values for each segment represent the percent
maximal uptake of the tracer. For the purpose of performing a
qualitative analysis, the same segments identified on the short-
axis and vertical long-axis tomograms were assigned a score
from 0 to 2 based on the visual assessment of relative tracer
activity: 0 5 noninterpretable; 1 5 mildly reduced activity; and
2 5 moderately or severely reduced activity. Each segment
demonstrating a perfusion abnormality during stress was then
classified as demonstrating complete reversibility (score 5 1),
partial reversibility (score 5 2) or a fixed defect (score 5 3)
during the rest phase. All scans were reviewed by two observers
(G.A.B., D.D.W.) who read the studies in random order and
who had no knowledge of the study type, identification and
clinical information. Segments with normal activity by visual
assessment were indicated by a blank entry. The consensus
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
SPECT 5 single-photon emission computed tomography (tomographic)
Tc-99m 5 technetium-99m
Tl-201 5 thallium-201
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interpretation of each segment was used to define normal and
abnormal segments. The quantitative values were used only as
a measure of activity within these segments. All quantitative
values are expressed as a fraction or percentage of the segment
of highest average uptake. These values were not corrected for
attenuation or normalized to a normal data base.
Coronary angiography. All patients underwent coronary
angiography with multiple views of the right and left coronary
arteries. This test and the two nuclear scans were completed
within 14 days. The films were reviewed by a single expert
investigator, and the site and severity of coronary artery
stenoses were recorded. Significant coronary stenosis was
defined as $50% reduction in the endolumen diameter of at
least one major coronary artery, as determined by quantitative
coronary angiography. Selected angiographic frames were dig-
itized off-line on a high resolution image processing system
(Imaging MDIC, Inc.). Calibration was achieved by measure-
ment of the diameter of the catheters used, which were of
known dimension. Coronary artery diameters were measured
at the site of stenosis and in adjacent nonstenotic segments
located both before and after the stenotic lesion; all ectatic
coronary arteries were excluded from analysis. Percent diam-
eter stenosis and area stenosis were calculated. The values
reported refer to percent diameter stenosis.
Statistical analysis. Results are presented as the mean
value 6 SEM, unless otherwise indicated. A chi-square test
was used to analyze differences in the number of segments
showing perfusion abnormalities between the two radiophar-
maceutical agents. The average magnitude of segmental per-
fusion defects that were concordantly identified by both tracers
was obtained and compared using a paired t test. More than
one abnormal segment was concordantly identified in some
patients, and this raises the question as to the statistical
independence of these multiple samples. Accordingly, an
analysis was performed using the patient as the unit of analysis.
In this analysis, concordant defects were averaged for each
patient, so each patient is weighted as a single statistical
sample. Moreover, the Wilcoxon signed-rank test was used so
that differences would not be weighted by individual defect
magnitude.
Results
Patients. Table 1 summarizes the clinical characteristics of
the patient cohort. All 26 patients were men (mean [6SD] age
62 6 9 years, range 44 to 75). Four patients had undergone
previous coronary artery bypass graft surgery, and two patients
had undergone previous percutaneous transluminal coronary
angioplasty. Seven patients had one-vessel, 7 patients had
two-vessel and 12 patients had three-vessel CAD. Three
patients had .50% left main CAD. A critical stenosis of the
left anterior descending coronary artery was present in 21
patients; 22 patients had a critical stenosis of the left circumflex
coronary artery; and 19 had right CAD. Six patients had a
known previous myocardial infarction.
Dipyridamole stress results. All 26 patients completed two
dipyridamole stress protocols: one with Tl-201 and the second
with Tc-99m tetrofosmin. Hemodynamic and ECG variables
monitored during dipyridamole infusion were not significantly
different between the two tests. Blood pressure and heart rate
response to the pharmacologic stress were similar for both
procedures (Table 2). The occurrence of chest pain and ECG
Figure 1. Polar maps and segments used for quantification. The 14
segments are divided to reflect basilar short-axis, mid-distal short-axis,
anteroapical (AA) and inferoapical (IA) segments and to include
approximately equal myocardial volume in each segment. ANT 5
anterior; INF 5 inferior; LAT 5 lateral; SEP 5 septal.
Table 1. Clinical Characteristics of 26 Study Patients
No. of Patients
Men* 26
Previous myocardial infarction 6
One-VD CAD 7
Two-VD CAD 7
Three-VD CAD 12
Previous CABG 4
Previous PTCA 2
LAD stenosis . 50% 21
LCx stenosis . 50% 22
RCA stenosis . 50% 19
LMCA stenosis . 50% 3
Q waves on baseline ECG 1
*Mean (6SD) age 62 6 9 years. CABG 5 coronary artery bypass graft
surgery; CAD 5 coronary artery disease; ECG 5 electrocardiogram; LAD 5 left
anterior descending coronary artery; LCx 5 left circumflex coronary artery;
LMCA 5 left main coronary artery; RCA 5 right coronary artery; VD 5 vessel
disease.
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ischemic changes were also similar. Ten patients had chest pain
and nine had $1.0 mm ST segment depression with dipyrida-
mole infusion.
SPECT imaging analysis. At least one perfusion defect
was detected in 25 of the 26 patients on both Tl-201 and
Tc-99m tetrofosmin SPECT images. Of the 364 segments
analyzed with Tc-99m tetrofosmin SPECT imaging, 24 were
considered noninterpretable by the two observers who read the
scans in a blinded manner. This was attributed to background
or gut activity, or both. None of the 364 segments analyzed on
Tl-201 SPECT images were judged to be noninterpretable.
Nevertheless, the 24 segments on Tl-201 SPECT images that
corresponded to the noninterpretable Tc-99m tetrofosmin
images were excluded from final analyses. Of these 24 defects
on Tl-201 SPECT scintigrams, 14 were normal, 7 were com-
pletely reversible and 3 were partially reversible.
Of the 340 segments interpretable by both techniques, 212
were concordantly normal, 26 were concordantly completely
reversible, 9 were partially reversible and 12 were concordantly
fixed or nonreversible (Table 3). The number of fixed defects
detected by each tracer was not statistically different (27 by
Tl-201 vs. 37 by Tc-99m tetrofosmin, p 5 NS). Tl-201 SPECT
identified more reversible and partially reversible defects than
did Tc-99m tetrofosmin SPECT (89 vs. 55, p 5 0.002).
Twenty-four segments interpreted as normal on Tc-99m
tetrofosmin SPECT corresponded to completely reversible
defects on Tl-201 SPECT images. In contrast, seven normal
Tl-201 segments corresponded to completely reversible defects
on Tc-99m tetrofosmin studies. After completion of the
blinded interpretation of the radionuclide studies, the location
of reversible defects was correlated with coronary angiographic
findings. Coronary vessels with .50% stenoses were identified
in supply zones for all reversible Tl-201 defects that showed
normal Tc-99m tetrofosmin uptake and all reversible Tc-99m
tetrofosmin defects read as normal on Tl-201 SPECT studies.
Finally, Tl-201 SPECT studies revealed defects in 13 (68%) of
the 19 coronary supply territories perfused by vessels with 50%
to 70% stenoses (10 reversible), whereas Tc-99m tetrofosmin
SPECT identified 7 defects (3 reversible) in the same 19
territories (p 5 0.05 for one-sided t test for difference in
reversible defects). Tl-201 and Tc-99m tetrofosmin SPECT
imaging identified an equal number of defects in territories
supplied by 71% to 99% stenoses or total occlusion (76% and
72%, respectively).
Quantitative analysis of SPECT images. Figure 2 shows
the mean defect magnitude (expressed as percent maximal
uptake) for completely reversible, partially reversible and fixed
defects concordantly graded on both Tl-201 and Tc-99m
tetrofosmin SPECT studies. Reversible defects were more
severe with Tl-201 (49 6 3% [mean 6 SEM]) than with
Tc-99m tetrofosmin (58 6 3%). This difference was highly
significant by either the paired t test (p 5 0.0001) or the
Wilcoxon test (p 5 0.004). Partly reversible defects were also
more severe for Tl-201 than for Tc-99m tetrofosmin (30 6 4%
vs. 45 6 5%). This difference was significant (p 5 0.02 by the
paired t test and p 5 0.03 by the Wilcoxon test). Fixed defects
averaged 38 6 3% for Tl-201 and 42 6 4% for Tc-99m
tetrofosmin. This difference was not significant by the paired t
test (p 5 0.06), but tested as significant by the Wilcoxon test
(p 5 0.03). We conclude that the difference for fixed defects
was insignificant or, at most, marginally significant.
Table 2. Hemodynamic and Electrocardiographic Changes*
Technetium-99m Tetrofosmin Thallium-201
Before Dipy
(mean 6 SD)
After Dipy
(mean 6 SD)
Before Dipy
(mean 6 SD)
After Dipy
(mean 6 SD)
SBP (mm Hg) 141 6 15 149 6 14 145 6 14 152 6 14
DBP (mm Hg) 80 6 7 80 6 8 84 6 8 83 6 9
HR (beats/min) 66 6 8 83 6 13 71 6 8 85 6 11
ST segment depression (mm) 0.6 6 0.12 0.5 6 0.15
*p 5 NS for all comparisons. DBP 5 diastolic blood pressure; Dipy 5 dipyridamole; HR 5 heart rate; SBP 5 systolic
blood pressure.
Table 3. Comparison of Thallium-201 and Technetium-99m Tetrofosmin Single-Photon Emission
Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments
Thallium-201
Technetium-99m Tetrofosmin
Total
Not
Readable
Reversible
Defects
Partially
Reversible
Fixed
Defects
Normal
Segments
Not readable 0 0 0 0 0 0
Reversible 7 26 3 9 24 69
Partly reversible 3 4 9 11 3 30
Fixed defects 0 2 4 12 9 27
Normal segments 14 7 0 5 212 238
Total 24 39 16 37 248 364
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Discussion
Technetium-99m 1,2-bis(bis[2-ethoxyethyl]phosphino)ethane
(Tc-99m tetrofosmin) is a lipophilic, cationic complex that is
rapidly cleared from the blood pool with intravenous injection
and that exhibits slow myocardial clearance without evidence
for delayed redistribution (1). This new imaging agent, like
Tc-99m sestamibi, accumulates in mitochondria. Only viable
myocardial tissue sequesters Tc-99m tetrofosmin, and its myo-
cardial uptake is reduced by metabolic inhibitors (such as
iodoacetic acid and 2,4-dinitrophenol) and excessive influx of
calcium (4–6). Takahashi et al. (7) showed that in rats, both
the initial and delayed retention of Tc-99m tetrofosmin was
sensitive to myocardial viability, as exhibited by significantly
lower uptake and retention in nonviable segments identified
1 h after reperfusion preceded by 1 h of total coronary
occlusion. Koplan et al. (6) showed that initial Tc-99m tetro-
fosmin uptake was similar to Tl-201 uptake in a dog model in
which rest left anterior descending coronary artery flow was
reduced by 50%, producing severe systolic dysfunction. In this
model, Tc-99m tetrofosmin myocardial activity was less than
Tl-201 activity after 2 h of redistribution.
Experimental studies. After intravenous injection, Tc-99m
tetrofosmin uptake in the myocardium is related to regional
blood flow (1,2). However, the relative Tc-99m tetrofosmin
activity underestimates blood flow .1.5 to 2.0 ml/min per g.
Glover et al. (2) found that both Tl-201 and Tc-99m tetrofos-
min uptake reached a plateau in the myocardium with
adenosine-induced hyperemia, but the Tc-99m tetrofosmin
plateau was lower than the Tl-201 plateau. In dogs with a
critical or mild left anterior descending coronary artery steno-
sis, Tl-201 and Tc-99m tetrofosmin uptake underestimated the
magnitude of the flow disparity, and the degree of underesti-
mation was greater for Tc-99m tetrofosmin. In the same study,
the investigators found that the first-pass myocardial extraction
fraction for Tc-99m tetrofosmin averaged 54%, which is lower
than the previously published extraction fraction values for
Tl-201, ranging from 82% to 88%, and is slightly lower than the
extraction fraction for Tc-99m sestamibi. The observation that
the flow heterogeneity between stenotic and normal myocar-
dial beds produced by adenosine stress in the presence of a
coronary stenosis is better resolved with Tl-201 than with
Tc-99m tetrofosmin in the canine model is most likely ex-
plained by the lower first-pass myocardial extraction fraction
for Tc-99m tetrofosmin. The experimental findings with Tc-
99m tetrofosmin with adenosine stress in this canine stenosis
model are similar to those reported previously with Tc-99m
sestamibi, in which the magnitude of adenosine-induced flow
heterogeneity was underestimated by both Tc-99m sestamibi
and Tl-201, but more so by Tc-99m sestamibi (8).
Clinical studies. In the clinical setting, Tc-99m tetrofosmin
planar or SPECT imaging with exercise stress has yielded high
quality images and good sensitivity and specificity values for
detection of CAD, and segmental perfusion abnormalities
were concordant with Tl-201 perfusion abnormalities when
patients underwent stress imaging with both tracers (3,9–12).
In the present study, dipyridamole Tc-99m tetrofosmin
scintigraphy was compared with Tl-201 scintigraphy using
quantitative SPECT imaging in a group of male patients who
underwent both tests as well as coronary angiography. Both
techniques yielded comparable detection rates of abnormal
scans in the 26 patients, but Tl-201 SPECT identified more
reversible and partially reversible perfusion defects than did
Tc-99m tetrofosmin SPECT (89 vs. 55 defects). Furthermore,
the average defect magnitude, expressed as percent normal,
was similar for defects concordantly graded as nonreversible,
whereas the defect magnitude for segmental perfusion abnor-
malities graded as completely or partially reversible on both
SPECT studies was more severe with Tl-201 than with Tc-99m
tetrofosmin. Thus, with dipyridamole stress imaging, both the
number of reversible defects and the magnitude of these
reversible defects were greater for Tl-201 scintigraphy than for
Tc-99m tetrofosmin scintigraphy, whereas the prevalence of
nonreversible defects and defect magnitude of these fixed
defects were comparable between the two radionuclide studies.
These findings are consistent with other clinical reports in
which a higher detection rate for reversible ischemia was seen
for Tl-201 versus Tc-99m tetrofosmin scintigraphy. Nakajima
et al. (13) reported 60% sensitivity for detecting $75% steno-
ses for Tc-99m tetrofosmin compared with 72% for Tl-201.
Specificity was comparable at 84%. In a study by Matsunari et
al. (14), 58 perfusion zones with initial Tl-201 defects had
corresponding normal Tc-99m tetrofosmin uptake.
The defect magnitude on Tc-99m tetrofosmin scans has
been reported by other investigators to be less than the defect
magnitude on Tl-201 scintigraphy performed in the same
patients. Matsunari et al. (15) found that the defect size on
exercise Tc-99m tetrofosmin images was smaller than the
defect size on Tl-201 images, as assessed by quantitative
SPECT imaging in 20 patients with CAD. Tamaki et al. (16)
reported a greater defect magnitude with Tl-201 than with
Tc-99m tetrofosmin, particularly in myocardial zones that
corresponded to reversible Tl-201 defects. Nevertheless, both
Tc-99m tetrofosmin imaging and Tl-201 imaging were highly
sensitive for detecting CAD.
Consistent with the findings in the present study, Cuocolo et
Figure 2. Bar graphs showing averages of defect magnitudes, including
only defects graded concordantly by both Tl-201 and Tc-99m tetrofos-
min as being reversible, partially reversible or fixed.
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al. (17) reported a lesser Tc-99m tetrofosmin defect magnitude
on adenosine stress images compared with exercise images
when exercise and vasodilator stress studies were performed in
the same patient group. In a more recent report by Cuocolo et
al. (18), 22 of 25 patients with CAD showed perfusion defects
on adenosine Tc-99m tetrofosmin tomography. Twenty-two of
those patients had at least one severe (.75%) coronary
stenoses, and 23% had a previous myocardial infarction.
Mahmood et al. (19) evaluated the diagnostic accuracy of
combined rest Tl-201 stress Tc-99m tetrofosmin SPECT using
adenosine infusion along with low level dynamic exercise for
detection of individual coronary artery stenoses. They studied
25 patients with known CAD. The overall coronary stenosis
detection rate was 80%, with a specificity of 70%. It should be
pointed out that more than 50% of the patients had a previous
myocardial infarction. The presence of previous myocardial
scar will always increase the detection rate of narrowings of
coronary arteries perfusing these nonviable myocardial zones.
Study limitations. Several limitations of this clinical obser-
vational study deserve mention: 1) The study included men
only. It is now accepted that SPECT imaging with Tc-99m
labeled radiopharmaceutical agents provides enhanced speci-
ficity for detection of CAD in women, without affecting
sensitivity. 2) Only sensitivity for detecting reversible ischemia
with vasodilator stress imaging was undertaken, without atten-
tion to comparing the specificity of the two imaging agents,
because patients with angiographically normal coronary arter-
ies or patients with a ,5% pretest likelihood of CAD not
undergoing angiography were not enrolled. Extrapolation of
the findings with dipyridamole stress to exercise stress cannot
be made because with exercise stress and consequent myocar-
dial ischemia and regional systolic dysfunction, Tc-99m tetro-
fosmin scintigraphy may yield better detection rates of revers-
ible ischemia than are seen with vasodilator stress. This study
used a standard same-day rest/stress protocol for Tc-99m
tetrofosmin. A 2-day protocol might have provided more
optimal study quality.
This study was designed to compare the detection of
perfusion defects and reversibility using conventional interpre-
tations of standard SPECT images. Quantitative analysis was
used to measure the actual tracer activity in segments graded
as normal or abnormal. Accordingly, we did not normalize
segments to compensate for attenuation or to a normal data
base. In comparing Tc-99m technetium and Tl-201 tracers,
some differences might be due to differences in photon atten-
uation or to reconstruction error caused by higher visceral
uptake in the proximity of the myocardium with Tc-99m
technetium tracers. To obtain a better understanding of the
quantitative magnitude of these differences, we averaged the
uptake of Tl-201 and Tc-99m technetium for segments that
were concordantly graded as normal. A profile of these aver-
age values for normal segments is shown in Figure 3. The
normal attenuation pattern of inferior and posterior segments
is clearly demonstrated. The differences between Tl-201 and
Tc-99m are less than we might have intuitively imagined. These
profiles of normal segments do not show major systematic
differences attributable to differential attenuation, scatter or
reconstruction error. The slightly greater attenuation of Tl-201
in the inferior segments is in accordance with calculations
using known attenuation coefficients. The difference in the
linear attenuation coefficients is often perceived intuitively to
be much greater than it is by actual measurement or calcula-
tion.
Clinical implications. Perhaps the most important finding
in this study is that dipyridamole Tc-99m tetrofosmin SPECT
yielded a reduced detection rate of reversible defects in the
distribution of mild to moderate stenoses in patients with
CAD, compared with Tl-201 SPECT. In contrast, dipyridamole
Tl-201 SPECT and Tc-99m tetrofosmin SPECT identified a
comparable number of defects in myocardial regions supplied
by stenoses .70%. It has not been determined whether this
limitation has any effect on the prognostic significance of a
normal Tc-99m tetrofosmin scan. Also, the implication of a
lower detection rate of multiple perfusion defects in patients
with multivessel disease needs to be ascertained.
Conclusions. With dipyridamole stress, 1) at least one
defect was seen on both Tl-201 and Tc-99m tetrofosmin
SPECT; 2) Tc-99m tetrofosmin SPECT identified fewer re-
versible defects than did Tl-201, but showed a similar number
of fixed defects; 3) the magnitude of reversible defects on
Tc-99m tetrofosmin images was less than the magnitude of
reversible defects on Tl-201 images, whereas the defect mag-
nitude of fixed segments was similar for both tracers; and 4)
reversible defects seen on Tl-201 SPECT but not on Tc-99m
tetrofosmin SPECT were predominantly regions perfused by
mild coronary stenoses.
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